A Narrative Review of Clinical Decision Support for Inpatient Clinical Pharmacists

Liang Yan¹ Thomas Reese² Scott D. Nelson³

¹ University of Utah College of Pharmacy, University of Utah Health, Salt Lake City, Utah, United States

² Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, Utah, United States

³Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, United States Address for correspondence Liang Yan, PharmD, University of Utah College of Pharmacy, University of Utah Health, 30 South 2000 E, Salt Lake City, UT 84112, United States (e-mail: Liang.Yan@pharm.utah.edu).

Appl Clin Inform 2021;12:199–207.

Abstract	Objective Increasingly, pharmacists provide team-based care that impacts patient care; however, the extent of recent clinical decision support (CDS), targeted to support the evolving roles of pharmacists, is unknown. Our objective was to evaluate the literature to understand the impact of clinical pharmacists using CDS. Methods We searched MEDLINE, EMBASE, and Cochrane Central for randomized controlled trials, nonrandomized trials, and quasi-experimental studies which evaluated CDS tools that were developed for inpatient pharmacists as a target user. The primary outcome of our analysis was the impact of CDS on patient safety, quality use of medication, and quality of care. Outcomes were scored as positive, negative, or neutral. The secondary outcome was the proportion of CDS developed for tasks other than medication order verification. Study quality was assessed using the Newcastle–Ottawa Scale.
	Results Of 4,365 potentially relevant articles, 15 were included. Five studies were randomized controlled trials. All included studies were rated as good quality. Of the
Keywords	studies evaluating inpatient pharmacists using a CDS tool, four showed significantly
 clinical decision 	improved quality use of medications, four showed significantly improved patient
support	safety, and three showed significantly improved quality of care. Six studies (40%)
 pharmacy 	supported expanded roles of clinical pharmacists.
information systems	Conclusion These results suggest that CDS can support clinical inpatient pharmacists
 inpatient care 	in preventing medication errors and optimizing pharmacotherapy. Moreover, an
 pharmacy 	increasing number of CDS tools have been developed for pharmacists' roles outside
 clinical informatics 	of order verification, whereby further supporting and establishing pharmacists as
 pharmacist 	leaders in safe and effective pharmacotherapy.

Background and Significance

Pharmacists' roles have expanded from traditional medication verification and dispensing to team-based patient care.^{1,2} Since the early 1970s, pharmacists have been tangentially involved with inpatient care through pharmacokinetic consultations. More recently, pharmacists are assuming providers' roles with

received August 25, 2020 accepted after revision December 14, 2020 collaborative practice agreements, which in some cases allow them to manage chronic health care conditions, such as diabetes and cardiovascular conditions.¹ Clinical pharmacists' roles are becoming more specialized through pharmacy residency training programs and specialty certification, and they are recognized as crucial members of the multidisciplinary health

© 2021. Thieme. All rights reserved. Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany DOI https://doi.org/ 10.1055/s-0041-1722916. ISSN 1869-0327. care team.³ As with providers, clinical pharmacists can be supported by health information technology, which has been considered a major factor in preventing medication errors and patient harm.²

Electronic health record (EHR) adoption and clinical decision support (CDS) implementation have also expanded in recent years.⁴ As of 2017, 94% of U.S. hospitals used an EHR system.⁴ CDS has been characterized as a health information technology that provides patient-specific information that is intelligently filtered and presented at appropriate times for decision making.^{5–7} CDS can be developed and refined through clinician observations, suggestions, and preferences.⁸⁻¹⁰ Some examples of CDS include passively providing clinicians with helpful information without interrupting their workflow or process, such as order facilitators (e.g., order sets and default settings), relevant information displays (e.g., info-buttons and links to additional resources), and even in-line displays of information (e.g., allergy or dose alerts).¹¹ CDS also includes active or interruptive alerting, such as hard-stop alerts and reminders. Unfortunately, even with more EHRs and CDS, deaths from medication errors still occur at an alarming rate.¹²

Pharmacists play a crucial role in identifying and preventing medication errors and CDS tools can help improve pharmacists' proficiency. A study found that 64% of prescribing errors could be prevented with pharmacists and CDS. The authors concluded that pharmacists' involvement is crucial for achieving maximum medication safety.¹ Moreover, systematic reviews have examined the impact of CDS on a broad range of pharmacy services, demonstrating the benefit of combining pharmacists and CDS.^{13,14} Pharmacists not only use the EHR and CDS, but they also contribute to their design and implementation.¹⁵ By including pharmacists in CDS design and implementation, the performance and reliability can be increased.¹⁶ With pharmacists assuming more clinical roles and more CDS tools being developed to support those roles, there is a need to examine the impact of CDS on clinical pharmacy practice. In this study we present a review of the literature regarding the impact of CDS and how it has evolved with clinical pharmacists. We anticipated that inpatient pharmacists using CDS will improve outcomes and that recent CDS supports pharmacists' roles beyond medication verification and dispensing (**Fig. 1**).

Methods

The study protocol was registered in PROSPERO (CRD420150 16952).¹⁷ We conducted a review of published studies to evaluate the impact of the CDS tools targeted at pharmacists in the inpatient setting. We aligned this review with the PRISMA guidelines and methods from the Cochrane Handbook.¹⁸

Search Strategy and Study Eligibility

Working with a medical librarian, we identified cohort studies, observational studies, randomized control trials, and quasiexperimental studies, by searching MEDLINE, EMBASE, and Cochrane Central between January 2009 and October 2020. The search strategy was developed for MEDLINE using PubMed and iteratively refined to capture preidentified studies (►Table 1). We combined keywords, headings, and other search strategies to develop search terms. Once the search strategy was refined with PubMed, we adapted to the other databases. Study inclusion criteria are provided in ►Table 2. Studies were excluded if there was no computerized system involved; the computerized system was not designed with pharmacists as the intended recipients; or the study was not in English. We used Covidence (Melbourne, Australia) to screen studies.¹⁹ Two reviewers




Fig. 1 Expanding roles of pharmacists.

Table 1 Pharmacy CDS review: PubMed search strategy

Search terms were translated to EMBASE and Cochrane Central database

"Medical Order Entry Systems/utilization" [Mesh] OR "Online Systems" [Mesh] OR "User-Computer Interface" [Mesh] OR "Medical Informatics Computing" [Mesh] OR "Medical Informatics" [Mesh] OR "Medical Informatics Applications" [Mesh] OR "Medical Order Entry Systems" [Mesh] OR "Pharmacist intervention" [All Fields] OR "Drug Prescriptions" [Mesh] OR "Electronic Prescribing" [Mesh] OR "Medication Systems" [Mesh] OR "Drug Therapy, Computer-Assisted" [Mesh] OR "Medication Errors" [Mesh] OR "Computerized p*" [All Fields] OR "Electronic p*" [All Fields] OR "CPOE" [All Fields] OR "Computerized order entry" [All Fields] OR "Electronic order entry" [All Fields] OR "Medication Reconciliation" [Mesh] OR "Pharmacists/organization and administration" [Mesh] OR "Drug Information Services" [Mesh] OR "Drug Interactions" [Mesh] OR "Guideline Adherence" [Mesh] OR "Practice Patterns, Pharmacists'" [All Fields] OR "Medication review" [All Fields] OR "Medication admin^{*}" [All Fields] OR "Clinical Pharmacy Information Systems" [Mesh] OR "Pharmacy Service, Hospital" [Mesh] OR "Pharmaceutical Services" [Mesh] OR "antimicrobial steward*" [tiab] OR "antibiotic steward*" [tiab] OR "pharmacokinetic service" [tiab] OR Pharmacotherapy [all fields]

, AND

"Decision Support Systems, Clinical" [Mesh] OR "Decision Making, Computer-Assisted" [Mesh] OR "Decision support" [All Fields] OR "electronic alerts" [All Fields] OR "computer alerts" [All Fields] OR "computerized alerts" [All Fields] OR CDS^{*}[All Fields] OR "Reminder Systems" [Mesh] OR Remind*[All Fields] OR Alert*[All Fields] OR Prompt*[All Fields] OR Notif*[All Fields] OR Interrupt*[All Fields] OR electronic display [all fields] AND "Pharmacists" [Mesh] OR pharmacist*[All Fields] AND [•]2009/01/01"[PDAT]: "2018/12/01"[PDAT]

Abbreviation: CDS, clinical decision support.

independently screened title/abstracts and full texts and a third reviewer resolved any disputes.

Quality Assessment

Since the included studies had different designs and outcomes, we used the Newcastle–Ottawa Scale to assess study quality.²⁰ Two reviewers independently assessed each included study. Additionally, it was noted whether the study conducted proper statistical analyses and whether the authors had mentioned possible contamination of the study groups.

Reporting and Analysis

Outcomes were grouped into three main categories: quality use of medication, drug and pharmacotherapy safety, and quality of care. Quality use of medication was defined as the accuracy of medication use and proper management of disease, such as appropriate dosing of medications. Drug and pharmacotherapy safety was defined as the safety of medication use, which was demonstrated by avoiding adverse events or death. Quality of care was defined as patient outcomes, which included parameters such as patient satisfaction and hospital length of stay.

The impact of the CDS intervention was characterized by assigning labels for each study result: " + " study favored the CDS intervention; " - " study favored the control group; "0" was no difference between the intervention and control groups; and "NS" the study did not conduct any statistical analysis or that there was no statistically significant data reported for the specified outcome.

We reported outcome data on whether studies demonstrated at least one positive outcome (i.e., general trend in favor of CDS for a prescribing, clinical, or patient outcome) and statistically significant improvements in favor of CDS on greater than or equal to 50% of outcomes. We chose to report trends as well as significant results given the likelihood that some studies were underpowered to detect statistically significant differences in outcomes. The outcome data are summarized in a narrative manner instead of a meta-analysis due to the heterogeneity of the study methodologies, comparison groups, intervention targets, and results.

Results

The search resulted in 4,365 articles. Based on title/abstract screening, 90 articles were selected for full-text review. Fifteen studies met the inclusion criteria (**-Fig. 2**). Most excluded studies were primarily focused on CDS used by providers and implementations outside the inpatient settings. Key features of the included studies are shown in **-Table 3**.²⁰⁻³⁴

Study Quality

Of the 15 included studies, 5 were randomized controlled trials,^{27,30,31,33,34} 6 were quasi-experimental,^{22,25,28,29,32,35} 2 were observational,^{23,26} and 2 were cohort studies.^{21,24} All of the studies had a control group and all 15 studies were deemed as good quality using the Newcastle–Ottawa Scale.

P: participant/population	Studies listing pharmacists among recipients of the CDS system in the inpatient setting.
I: intervention	The described CDS system had to provide patient-specific information and/or generate information in an electronic format.
C: comparator/control	A comparison of performance of the CDS to routine care or other CDS or computerized prescriber order entry (CPOE) systems.
O: outcome	The primary outcome of the study had to include patient care, clinician effect, or processes of care. The studies also had to report measured or quantifiable outcomes, such as cost, patient outcomes, adverse drug events, clinical interventions, etc.

Table 2 Study inclusion criteria

Abbreviation: CDS, clinical decision support.

Identification

Screening

Eligibility




Fig. 2 PRISMA diagram.

Study Characteristics

Study outcomes were analyzed in three main groups, including quality use of medication, drug and pharmacotherapy safety, and quality of care (**-Table 3**). Four studies examined the quality use of medications,^{23,27,31,35} seven studies looked at drug and pharmacotherapy safety,^{22,24,25,29,30,33,34} and five studies evaluated the quality of care.^{21,25,26,28,32} One study qualified as both drug and pharmacotherapy safety and quality of care. Pharmacists interacted directly with patients in one study through medication reconciliation³² and all other CDS systems did not have pharmacist-patient interactions: most of the data were based on measured laboratory results and recorded patient information by nurses and laboratory technicians.

Pharmacists were warned of potential errors through CDS alerting in 11 of the studies. For example, two studies had alerts that interrupted a pharmacist's workflow when a patient had an abnormal serum creatinine.^{30,34} These alerts were designed to prevent medication-caused acute kidney injury and therefore required the pharmacist's immediate attention. None of the included studies discussed alert fatigue or workflow disruption.

Other CDS interventions provided support without interrupting pharmacists' workflow. For example, two studies examined a CDS system that calculated the dose of antibiotics for the pharmacist.^{23,35} Another study evaluated a CDS system that helped identify medication reconciliation errors.³² Finally, one study used CDS to examine cost-benefit analysis of medication use.27

	Quality		Participants (n)	Intervention	Control	Outcome measures	Study results	Statistically significant
Prospective Good 2,649 and 3,064 interven- cohort study (preintervention) and 2 (CDS intervention)		2,649 and 3,064 interven- tions in phase 1 (preintervention) and 2 (CDS intervention)		Electronic prompt that asks pharmacist to re-evaluate his rejected pharmacotherapy intervention	Preintervention and multidisciplinary team	Quality of care: re-evaluated a pharmacist-rejected intervention to determine it is accurate	 (+) Decreased number of inappropriate rejections by 56%. 	NS
Quasi-experimental Good 5,006 total alerts during the study time period. 404 decision difference between CDS alert and pharmacist	Good	5,006 total alerts during the study time period. 404 decision difference between CDS alert and pharmacist		Electronic alert checks dosing error of drug orders	Pharmacist checks	Safety: dose check	 (+) 50% overdoses detected by CDS while 14% detected by pharmacist. 	NS
Prospective Good 87 patients on selected observational antibacterial drugs that study calculation calculation		87 patients on selected antibacterial drugs that require creatinine for dose calculation		Electronic antimicrobial dose alert provides dosing advice based on 24-hour creatinine clearance	Pharmacist review	QUM: "antimicrobial dose based on SCr" (ADC) accuracy alert and pharmacist workload	(+) 78.5% correct dosing prescription. 13.4% overdosed, and 8.1% underdosed. Pharma- cist time per patient reduced by 76.5%.	NS
Prospective Good 50 patients followed by cohort study clinical pharmacists		50 patients followed by clinical pharmacists		CDS DDI alert system	Pharmacist check	Safety: compare rate of DDI and rate of acceptance between CDS DDI alert and pharmacist verifications	 (-) 240: 6 DDIs by pharmacist: CDS (-) 81%: 0 accepted advise by physician 	Statistically significant
RCT Good Patient started on tobramy- cin or amikacin during study period (97 amikacin patients and 119 tobramycin patients)		Patient started on tobramy- cin or amikacin during study period (97 amikacin patients and 119 tobramycin patients)		CDS dosing selection for patient initiating on tobramycin or amikacin	Preintervention	QUM: pharmacist calculated amikacin/tobramycin dose alert (within $\pm10\%$ of the study reference standard)	(+) 40% dosing accuracy in the pre-CDS arm to 80% in the post-CDS arm	Statistically significant
Quasi-experimental Good 171 patients > 18 years of age admitted to medical and surgical services with an eGFR < 60 mL/min	Good	171 patients >18 years of age admitted to medical and surgical services with an eGFR < 60 mL/min		CDS with drug-allergy checking, formulary decision support, and DDI checking	Preintervention	Safety, quality of care: evaluate the efficacy of CDS on the frequency of appropriate prescriptions.	(+) 65% pre-CDS, 86% after intervention. Correct prescrip- tion based on renal function	Statistically significant
Prospective Good Patient admitted in 5 ran- observational domly chosen consecutive adays. 150 alerts generated by basic CDS and 384 alerts generated by advanced CDS		Patient admitted in 5 ran- domly chosen consecutive days. 150 alerts generated by basic CDS and 384 alerts generated by advanced CDS		Advanced medication alert CDS with multiple functionality	Basic medication alert CDS	Quality of care: compare the performance of two medication alert CDSs	 (+) Advanced CDS has higher positive predicted value (17%) compared with basic CDS (5.8%). 	Statistically significant
Type Study Participants (n) quality		Participants (<i>n</i>)		Intervention (types of CDSS)	Control	Outcome measures	Study results	Statistically significant
RCT and Good 361 patients admitted to the cost-effective hospital within the study timeline were randomized into each group		361 patients admitted to the hospital within the study timeline were randomized into each group		CDS integrated with STOPP/START criteria for elderly patients	Preintervention	QUM: cost-effectiveness analysis of SPRM/CDSS for elderly patients	 (+) CDS group was associated with a decrease of €807 in mean health care cost (+) Decrease in the mean number of ADR events per patient 	NS
Quasi-experimental Good 28 delinium patients included in the preintervention arm and 33 patients at the intervention arm.	Good	28 delirium patients included in the preintervention arm and 33 patients at the intervention arm.		Real-time CDS alert that notifies pharmacist of delirium patient that meet recommendation criteria	Preintervention	Quality of care: compare the delirium incidence, length of stay, and ventilator duration between CDS and control group	 (+) CDS group had a nonsignificant trend in decreased incidence of delirium, ICU length of stay, and ventilator duration. (+) CDS group had a significantly shorter hospital LOS. 	Statistically significant
								(Continued)

Table 3 (Continued)

Quasi-experimental	Good	Any admitted patient who can potentially develop hyperkalemia.	High K level alert CDS that notifies pharmacists when a drug order will further increase K level	Preintervention	Safety: effect of a hyperka- lemia ADE alert	(+) 48:14 pre-CDS; post-CDS patients had hyperkalemia that required treatment.	Statistically significant
	Good	396 patients with an acute 0.5 mg/dL change in serum creatinine over 48 hours and a nephrotoxicity or renally cleared medication order.	Web-based dynamic surveillance CDS monitors AKI by clinical pharmacists	Preintervention (pa- tient with no sur- veillance tool)	Safety: AKI-related ADEs and potential ADEs within the CDS group compared with control group	(0) No statistical difference was observed between intervention and controlled group	NS
Quasi-experimental	Good	321 patients admitted in the cardiopneumology unit during the study period	"Medication history documentation" CDS integrated with electronic clinical history	Preintervention	Quality of care: CDS intends to decrease medication rec- onciliation error	(+) The mean number of reconciliation errors per patient: preintervention, 4.4 \pm 3.2; during intervention, 1.8 \pm 2.6; postintervention, 3.9 \pm 3.7	Statistically significant
	Good	1,833 patients aged >65 years admitted to specialist services	CDS with structured pharmacist review of medication (SPRM) to prevent ADR	Preintervention (standard pharma- ceutical care without CDS)	Safety: ADR risk reduction between CDS and control group	(+) Provider implemented 54.8% of SPRM/CDSS prescrib- ing recommendations. Ninety- one ADRs occurred in 78 control patients (20.7%) compared with 61 ADRs in 50 CDS group patients (13.9%), an absolute risk reduction of 6.8%.	Statistically significant
	Good	2,393 patients ≥18 years old with stage 1 or greater acute kidney injury	Current SCr-based AKI alert CDS sends notification to providers	Preintervention	Safety: ranking of clinical outcomes, maximum relative change in creatinine, dialysis, and death, within 7 days of randomization	(0) There was no difference between the two groups comparing the creatinine, dialysis, and death at 7 days.	Statistically significant
Quasi-experimental	Good	332 patients receiving IV antibiotics during the entire study period	CDS converting IV antibiotics to PO dose per pharmacist	Preintervention	QUM: assessing antibiotic IV-PO conversion rate before and after CDS implementation	 (+) IV-PO conversion rate was 29% (preintervention), 35% (1 month postintervention), 71% (3 months post), and 74% (15 months post) 	Statistically significant

Applied Clinical Informatics Vol. 12 No. 2/2021 © 2021. Thieme. All rights reserved.

Abbreviations; ADE, adverse drug event; ADR, adverse drug reaction; AKI, acute kidney injury; CDS, clinical decision support; CDSS, clinical decision support system; DDI, drug-drug interaction; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; IV, intravenous; LOS, length of stay; PO, per oral; RCT, randomized controlled trial; SCr, serum creatinine.

Note: " + " meaning that the study favored the CDS intervention. " - " meaning that the study favored the control group. "0" meaning that there was no difference between the intervention and the control groups. "NS" meaning that the study did not conduct any statistical analysis or that there was no statistically significant data reported for the specified result. "QUM" meaning quality use of medication.

Review of Clinical Decision Support Yan et al. 205

CDS Intervention Analysis

Eight studies significantly favored the CDS intervention^{25,26,28,29,31–33,35}; 20% of the studies presented results that favored the CDS intervention without statistical significance^{21,23,27}; 13% of the studies favored the control groups^{22,24}; and 13% of the studies showed that the CDS interventions had no difference compared with the control group.^{30,34} One study²⁴ favors pharmacists' check over CDS; however, this was explained by the authors that the CDS was self-developed and lacks a high level of specificity for drug–drug interactions (DDIs).

CDS interventions covered a wide range pharmacists' practice, including dynamic monitoring, drug safety in low kidney function patients, medication safety in patients with QT prolongation, dosing calculation, medication reconciliation, and general medication use and safety. Eleven of the 14 studies examined CDS application outside medication verification.^{21,23,27-35} Among the 11 studies, 82% presented results that favored the CDS intervention with statistical significance,^{21,23,27-29,31-33,35} 18% of the studies showed that the CDS interventions had no difference compared with the control group,^{30,34} and no study favored the control group.

Discussion

This study demonstrated that CDS interventions developed for clinical pharmacists can improve health care outcomes. Notably, all studies that evaluated quality use of medication and quality of care showed improved outcomes. Moreover, CDS seems to be evolving with clinical pharmacists' roles, since the majority of studies evaluated an intervention outside order verification tasks.

When compared with CDSs in other settings, studies conducted in community pharmacy practice examined workflow consequences, interactions with patients more frequently, and relied less on EHR information, such as laboratory results.^{15,36} Previous studies have examined CDS that supports prescribing in community and hospital pharmacy settings.^{13,36} These studies concluded that workflow disruption and alert fatigue were major issues causing pharmacists to ignore CDS alerts and prompts. In the present review, we did not identify or conclude that workflow or alert fatigue was a problem. The lack of alert fatigue discussion in the included studies may be the result of the inpatient setting where patient data can be used to refine alert triggers, making alerts more specific. However, we do believe that alert fatigue is still an issue for pharmacists in the inpatient setting given the amount of CDS.³⁷

One of the aims of this review was to examine how CDS is meeting the need of clinical pharmacists providing patient care. We found the majority of CDS interventions still focus on drug dosing, DDIs, and identifying or preventing adverse effects; however, we did find CDS interventions that have expanded to other clinical areas, such as managing acute kidney injury, and managing cardiovascular diseases. Also, CDS interventions supported specialized services in the emergency department, geriatric wards, trauma units, and other units.^{9–11,15–19,21,22} These findings suggest that CDS is supporting specialized and decentralized pharmacists' roles in a variety of clinical domains in hospital departments.

Concerns remain on whether advanced CDS systems will replace pharmacists and reduce the number of pharmacy jobs. Based on the included studies, this does not seem to be the case as the majority of CDS interventions were basic alerts and prompts. Two studies used CDS to calculate antimicrobial dosing, but the ultimate decision was still based on pharmacists' discretion. There were no signs that implementation of CDS could replace clinical pharmacists, rather it is more likely that CDS is helping pharmacists increase their efficiency and patient safety.³⁸

Limitations of this study should be noted. First, we were unable to conduct meta-analysis due to the heterogeneity of included studies. Second, we only queried studies published in three databases, which means there could be other published (or unpublished) studies that were not included. Finally, the majority of the studies showed a benefit from using CDS, which suggests publication bias may be present.

Conclusion

With more than 73% of studies examining CDS outside medication verifications and 82% of studies favoring the intervention, these findings suggest CDS implementations targeted toward clinical pharmacists have been increasing and improving as pharmacists' roles are becoming more clinical and patient-orientated. We anticipate that as the clinical pharmacy's role expands into more specialized health care fields, CDS interventions will also expand to support pharmacists and improve patient care.

Clinical Relevance Statement

This review showed that between 2009 and 2020, multiple studies examined clinical pharmacist related nonverification CDS and showed positive results that the CDS facilitates pharmacist's workflow in clinical settings. These CDSs were developed to accommodate the expanding roles of pharmacists. This review has indicated continuous progress for pharmacists to contribute in clinical patient care and makes pharmacist an important member in medical interdisciplinary team.

Multiple Choice Questions

- 1. Which of the following pharmacists' roles can be best facilitated by inpatient CDS systems (up to 2)?
 - a. Pharmacists supervise the medicine supply chain.
 - b. Pharmacists counsel patients on safe and effective medicine use.
 - c. Pharmacists advise other health care professionals about safe and effective medicine use.
 - d. Pharmacists monitor patient's health conditions and determine safety and efficacy of their current medication.

Correct Answer: The correct answers are options a and d. CDS systems can be implemented to monitor patient's health conditions or decrease medicine cost. CDS cannot replace pharmacists to counsel patients or advise health care professionals.

- 2. Which of the following is not a keyword used to determine included studies of this review?
 - a. Pharmacist
 - b. Computerized
 - c. Clinical
 - d. Doctor

Correct Answer: The correct answer is option d. This study reviews CDSs used by pharmacists in inpatient/ clinical settings. Doctors are not part of the inclusion criteria.

Protection of Human and Animal Subjects

There were no human subjects involved in this project.

Conflict of Interest

None declared.

Acknowledgment

This study was supported by University of Utah College of Pharmacy. Also, we are very thankful to the editorial board of Applied Clinical Informatics journal for their valuable and constructive comments.

References

- ¹ Dolovich L, Austin Z, Waite N, et al. Pharmacy in the 21st century: enhancing the impact of the profession of pharmacy on people's lives in the context of health care trends, evidence and policies. Can Pharm J 2018;152(01):45–53
- 2 Francis J, Abraham S. Clinical pharmacists: bridging the gap between patients and physicians. Saudi Pharm J 2014;22(06): 600-602
- ³ Carter BL. Evolution of clinical pharmacy in the USA and future directions for patient care. Drugs Aging 2016;33(03):169–177
- 4 Saiyed SM, Davis KRKD, Kaelber DC. Differences, opportunities, and strategies in drug alert optimization-experiences of two different integrated health care systems. Appl Clin Inform 2019;10(05):777–782
- 5 Health IT. Clinical decision support. The Office of the National Coordinator for Health Information Technology. Accessed January
 8, 2021 at: https://www.healthit.gov/sites/default/files/page/ 2018-04/Optimizing_Strategies_508.pdf
- 6 Lainer M, Mann E, Sönnichsen A. Information technology interventions to improve medication safety in primary care: a systematic review. Int J Qual Health Care 2013;25(05):590–598
- 7 Ibáñez-Garcia S, Rodriguez-Gonzalez C, Escudero-Vilaplana V, et al. Development and evaluation of a clinical decision support system to improve medication safety. Appl Clin Inform 2019;10 (03):513–520
- 8 Ozkaynak M, Metcalf N, Cohen DM, May LS, Dayan PSMR, Mistry RD. Considerations for designing EHR-embedded clinical decision support systems for antimicrobial stewardship in pediatric emergency departments. Appl Clin Inform 2020;11(04):589–597
- 9 Wang J, Liang H, Kang H, Gong Y. Understanding health information technology induced medication safety events by two conceptual frameworks. Appl Clin Inform 2019;10(01):158–167

- 10 Unberath P, Prokosch HU, Gründner J, Erpenbeck M, Maier C, Christoph J. EHR-independent predictive decision support architecture based on OMOP. Appl Clin Inform 2020;11(03):399–404
- 11 Wright A, Sittig DF, Ash JS, et al. Development and evaluation of a comprehensive clinical decision support taxonomy: comparison of front-end tools in commercial and internally developed electronic health record systems. J Am Med Inform Assoc 2011;18 (03):232–242
- 12 Lyell D, Magrabi F, Coiera E. Reduced verification of medication alerts increases prescribing errors. Appl Clin Inform 2019;10(01): 66–76
- 13 Curtain C, Peterson GM. Review of computerized clinical decision support in community pharmacy. J Clin Pharm Ther 2014;39(04): 343–348
- 14 Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 2015;8(01):2–10
- 15 Nelson SD, Poikonen J, Reese T, El Halta D, Weir C. The pharmacist and the EHR. J Am Med Inform Assoc 2017;24(01):193–197
- 16 Saverno KR, Hines LE, Warholak TL, et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. J Am Med Inform Assoc 2011; 18(01):32–37
- 17 Nelson S, Newbold J, Reese T, et al. Computerized clinical decision support systems for clinical pharmacy in the MeaningfulUse Era: a systematic review. National Institute for Health Research. Published 2015. Accessed January 8, 2021 at: https://www.crd. york.ac.uk/PROSPERO/display_record.php?RecordID=16952
- 18 Chandler J, Higgins JPT, Deeks JJ, Davenport C, Clarke MJ. Chapter 1: Introduction. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, eds. Cochrane Handbook for Systemic Reviews of Interventions version 5.2.0. 2017:1–11
- 19 Covidence. Accessed January 8, 2021 at: https://www.covidence.org/
- 20 Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. The Ottawa Hospital Research Institute. Published 2019. Accessed January 8, 2021 at: http://www.ohri.ca/programs/ clinical_epidemiology/oxford.asp
- 21 Aziz MT, Rehman TU, Qureshi S, Andleeb S. Effects of multidisciplinary teams and an integrated follow-up electronic system on clinical pharmacist interventions in a cancer hospital. Int J Clin Pharm 2017;39(06):1175–1184
- 22 Boussadi A, Caruba T, Karras A, et al. Validity of a clinical decision rule-based alert system for drug dose adjustment in patients with renal failure intended to improve pharmacists' analysis of medication orders in hospitals. Int J Med Inform 2013;82(10):964–972
- 23 Claus BOM, Colpaert K, Steurbaut K, et al. Role of an electronic antimicrobial alert system in intensive care in dosing errors and pharmacist workload. Int J Clin Pharm 2015;37(02):387–394
- 24 Cornu P, Steurbaut S, Soštarić S, Mrhar A, Dupont AG. Performance of a clinical decision support system and of clinical pharmacists in preventing drug-drug interactions on a geriatric ward. Int J Clin Pharm 2014;36(03):519–525
- 25 Díaz A, Saez de la Fuente J, Esteva L, et al. Drug prescribing in patients with renal impairment optimized by a computer-based, semi-automated system. Int J Clin Pharm 2013;35(06): 1170–1177
- 26 Eppenga WL, Derijks HJ, Conemans JMH, Hermens WAJJ, Wensing M, De Smet PAGM. Comparison of a basic and an advanced pharmacotherapy-related clinical decision support system in a hospital care setting in the Netherlands. J Am Med Inform Assoc 2012;19(01):66–71
- 27 Gallagher J, O'Sullivan D, McCarthy S, et al. Structured pharmacist review of medication in older hospitalised patients: a costeffectiveness analysis. Drugs Aging 2016;33(04):285–294

- 28 Lightfoot M, Sanders A, Burke C, Patton J. Clinical pharmacist impact on intensive care unit delirium: intervention and monitoring. Hosp Pharm 2019;54(03):180–185
- 29 Mansour H, Dilkhush D, Lannigan J, Whalen KL. The impact of a computerized potassium alert on adverse drug events and pharmacists' interventions. J Pharm Technol 2010;26(02):55–59
- 30 McCoy AB, Cox ZL, Neal EB, et al. Real-time pharmacy surveillance and clinical decision support to reduce adverse drug events in acute kidney injury: a randomized, controlled trial. Appl Clin Inform 2012;3(02):221–238
- 31 Cox Z, Nelsen C, Waitman L, McCoy J, Peterson J. Clinical decision support improves initial dosing and monitoring of tobramycin and amikacin. Am J Health Syst Pharm. 2008;23(01):1–7
- 32 García-Molina Sáez C, Urbieta Sanz E, Madrigal de Torres M, Vicente Vera T, Pérez Cárceles MD. Computerized pharmaceutical intervention to reduce reconciliation errors at hospital discharge in Spain: an interrupted time-series study. J Clin Pharm Ther 2016;41(02):203–208
- 33 O'Sullivan D, O'Mahony D, O'Connor MN, et al. Prevention of adverse drug reactions in hospitalised older patients using a

software-supported structured pharmacist intervention: a cluster randomised controlled trial. Drugs Aging 2016;33(01):63-73

- 34 Wilson FP, Shashaty M, Testani J, et al. Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial. Lancet 2015;385(9981):1966–1974
- 35 Kan T, Kwan D, Chan T, Das P, Raybardhan S. Implementation of a clinical decision support tool to improve antibiotic IV-to-oral conversion rates at a community academic hospital. Can J Hosp Pharm 2019;72(06):455–461
- 36 Robertson J, Walkom E, Pearson SA, Hains I, Williamsone M, Newby D. The impact of pharmacy computerised clinical decision support on prescribing, clinical and patient outcomes: a systematic review of the literature. Int J Pharm Pract 2010;18 (02):69–87
- 37 Reese TJ, Kawamoto K, Del Fiol G, et al. When an alert is not an alert: a pilot study to characterize behavior and cognition associated with medication alerts. AMIA Annu Symp Proc 2018: 1488–1497
- 38 Friedman CPA. A "fundamental theorem" of biomedical informatics. J Am Med Inform Assoc 2009;16(02):169–170